Free Trial
NASDAQ:INVA

Innoviva (INVA) Stock Price, News & Analysis

Innoviva logo
$18.46 +0.21 (+1.15%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$18.45 -0.01 (-0.03%)
As of 08/7/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Innoviva Stock (NASDAQ:INVA)

Key Stats

Today's Range
$18.21
$18.97
50-Day Range
$18.17
$21.80
52-Week Range
$16.67
$22.00
Volume
1.55 million shs
Average Volume
785,930 shs
Market Capitalization
$1.16 billion
P/E Ratio
59.55
Dividend Yield
N/A
Price Target
$40.33
Consensus Rating
Buy

Company Overview

Innoviva Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

INVA MarketRank™: 

Innoviva scored higher than 86% of companies evaluated by MarketBeat, and ranked 131st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Innoviva has only been the subject of 2 research reports in the past 90 days.

  • Read more about Innoviva's stock forecast and price target.
  • Earnings Growth

    Earnings for Innoviva are expected to grow by 369.70% in the coming year, from $0.33 to $1.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Innoviva is 59.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Innoviva is 59.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.

  • Price to Book Value per Share Ratio

    Innoviva has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.02% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Innoviva has recently decreased by 2.93%, indicating that investor sentiment is improving.
  • Dividend Yield

    Innoviva does not currently pay a dividend.

  • Dividend Growth

    Innoviva does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.02% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Innoviva has recently decreased by 2.93%, indicating that investor sentiment is improving.
  • News Sentiment

    Innoviva has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Innoviva this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innoviva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.25% of the stock of Innoviva is held by insiders.

  • Percentage Held by Institutions

    99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Innoviva's insider trading history.
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

Innoviva (INVA) Q2 Sales Jump 64%
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
See More Headlines

INVA Stock Analysis - Frequently Asked Questions

Innoviva's stock was trading at $17.35 at the beginning of the year. Since then, INVA shares have increased by 6.4% and is now trading at $18.46.

Innoviva, Inc. (NASDAQ:INVA) posted its earnings results on Wednesday, August, 6th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.20. The biotechnology company earned $100.28 million during the quarter, compared to analyst estimates of $87.10 million. Innoviva had a trailing twelve-month return on equity of 18.99% and a net margin of 10.44%.

Innoviva's top institutional investors include Boston Partners (0.96%), Denali Advisors LLC (0.53%), Allspring Global Investments Holdings LLC (0.47%) and Hussman Strategic Advisors Inc. (0.33%).
View institutional ownership trends
.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/06/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CIK
1080014
Employees
100
Year Founded
1996

Price Target and Rating

High Price Target
$55.00
Low Price Target
$26.00
Potential Upside/Downside
+118.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.31
Trailing P/E Ratio
59.55
Forward P/E Ratio
55.94
P/E Growth
N/A
Net Income
$23.39 million
Net Margins
10.44%
Pretax Margin
-12.53%
Return on Equity
18.99%
Return on Assets
10.06%

Debt

Debt-to-Equity Ratio
0.40
Current Ratio
2.48
Quick Ratio
2.30

Sales & Book Value

Annual Sales
$358.71 million
Price / Sales
3.23
Cash Flow
$3.46 per share
Price / Cash Flow
5.33
Book Value
$11.03 per share
Price / Book
1.67

Miscellaneous

Outstanding Shares
62,780,000
Free Float
61,363,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.38

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:INVA) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners